
Mocetinostat
Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others. — DrugBank
- IUPAC name
- N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
- Molecular formula
- C23H20N6O
- Molecular weight
- 396.4 g/mol
- Exact mass
- 396.16985928 Da
- XLogP3
- 2.8
- Topological polar surface area
- 106.0 Ų
- Hydrogen-bond donors
- 3
- Hydrogen-bond acceptors
- 6
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:94525
- ChEMBL:CHEMBL272980
- EPA DTXSID:DTXSID80222945
- PubMed:33770205
- PubMed:27255383
- PubMed:26775640
- PubMed:26378038
- PubMed:24200994
- PubMed:22706966
- PubMed:22382879
- PubMed:22282194
- PubMed:22123590
- PubMed:22033282
- PubMed:21668391
- PubMed:21650221
Retrieved from NIH PubChem on 2026-09-02 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.